Early use of Uptravi reduces risk of disease progression in PAH patients
Phase III study finds risk reduced by 52% compared with control group
Read More
Tag: Uptravi
NHS England to fund Actelion’s Uptravi
Actelion Pharmaceuticals has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH), can now be treated with Uptravi.
Read More
PAH patients in England denied access to Actelion’s Uptravi on NHS
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Read More
Wales backs NHS use of Actelion’s Uptravi for PAH
Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).
Read More
Five therapies endorsed for use on NHS Scotland
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read More
SMC bars access to Actelion’s Uptravi on NHS Scotland
Actelion says it is disappointed with a decision by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi.
Read More
EU safety review backs continued use Uptravi for PAH
European regulators have ruled that Actelion’s Uptravi can continue to be used as per its prescribing information to treat patients with pulmonary arterial hypertension, a life-threatening condition involving abnormally high blood pressure in the arteries of the lungs.
Read More
EU regulators allow use of Uptravi during safety review
European regulators are advising that doctors can continue prescribing Actelion’s Uptravi for pulmonary arterial hypertension while an investigation into its safety is completed.
Read More
European approval for Actelion’s Uptravi in PAH
EU regulators have issued a green light for Actelion’s Uptravi, offering a new treatment option to patients with pulmonary arterial hypertension.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
